

of 47 (34%) we noticed cytokeratines-positive cells in SLNs only, being the other nodes negative. Our skip metastases rate was 8.5% (4/47 patients).

**Conclusion:** We found that SLN reflects the status of all the other pericolic nodes. Thus, a more accurate analysis performed on SLN in colon cancer may help to identify an additional patient population who should be treated with adjuvant chemotherapy.

200

POSTER

### Efficacy of intraoperative cytological examination

N. Volchenko, Z.D. Gladunova, E.N. Slavnova. *P.A. Herzen Cancer Research Institute, department of cytology, Moscow, Russian Federation*

**Background:** The aim of the study was to assess the efficacy of intraoperative cytological examination.

**Materials and methods:** The efficacy of the method was analyzed on the basis of 2647 specimens obtained from 553 patients who were operated in 2002. Cytological specimens included biopsies, scrapes, imprints and body cavity fluids. We examined 609 biopsies of primary tumors and tumor-like masses from different sites, 44 liver biopsies, 756 lymph node scrapes, 330 surgical margins' scrapes (mainly breast, bronchi and esophagus), 232 scrapes and imprints from serosae, 213 scrapes and imprints from peritumoral tissues, 463 samples of pleural and peritoneal fluid. Cytological smears were stained using Papanicolaou's modified method (azur-eosin staining). The results of intraoperative cytological assessment were compared to the conventional histopathological examination.

**Results:** An overall accuracy of intraoperative cytological examination was 98.3%; false negative results were observed in 1%, false positive – 0.7%. The accuracy of intraoperative cytological examination for different cytological specimens was as follows: lymph node metastases – 99.2%, primary tumors – 95.9%, surgical margins – 99.7%, serosae – 97.8%, peritumoral tissues – 98.1%, hepatic lesions – 97.7%.

**Conclusion:** Intraoperative cytological examination is a highly accurate method of morphological diagnosis. Still some cytograms of malignant tumors were misinterpreted. In case of lymph nodes micrometastases and high-grade sinus-histiocytosis were the reasons of failure. In case of fluids and serosae non-specific mesothelial changes accounted for false results. In some instances it was difficult to differentiate tumor cells from non-specific inflammation.

201

POSTER

### Analysis of G/A SNP change at position 2494 in the E-cadherin gene in Italian patients with sporadic, diffuse gastric cancer

A. Ruzzo<sup>1</sup>, F. Graziano<sup>2</sup>, A. Costagliola<sup>1</sup>, E. Testa<sup>2</sup>, F. Andreoni<sup>3</sup>, F. Arduini<sup>4</sup>, A. Antolini<sup>4</sup>, I. Bearzi<sup>4</sup>, A. De Gaetano<sup>5</sup>, M. Magnani<sup>1</sup>.

<sup>1</sup> University of Urbino "Carlo Bo", Biological Chemistry, Urbino, Italy; <sup>2</sup> Hospital of Urbino, Medical Oncology Unit, Urbino, Italy; <sup>3</sup> University of Urbino "Carlo Bo", Center of Biotechnology, Urbino, Italy; <sup>4</sup> University of Ancona, Dept. of Histopathology, Ancona, Italy; <sup>5</sup> Catholic University of Rome, Laboratory of Biostatistics, Rome, Italy

Current investigations are studying new E-cadherin gene (CDH1) mutations that may be causative of diffuse gastric cancer susceptibility. Recently, a novel CDH1 germline variant with G/A nucleotide change at cDNA position 2494 has been found in Japanese patients with familial diffuse gastric cancer. The consequent amino acid variation (Val/Met) may alter the binding activity of B-catenin and the adhesive function of the E-cadherin protein. Data on the 2494 G/A nucleotide change in sporadic cases of diffuse gastric cancer and in patients of Western origin are lacking. We have investigated its frequency in Italian cases of sporadic, diffuse gastric cancer and healthy controls.

Peripheral blood samples were collected from consecutive patients with sporadic, diffuse gastric cancer and healthy controls who were natives of the District of Urbino, Region Marche, Central Italy. After DNA extraction, standard techniques for molecular analyses were used to investigate the 2494 G/A germline nucleotide change in CDH1 cDNA.

None of 48 patients and 48 controls showed the G/A 2494 nucleotide change. Assuming a binomial distribution of the mutation among individuals and according to zero mutations in 48 patients, the 95% upper bound for the underlying mutation frequency was 7.4%.

The novel CDH1 nucleotide change is uncommon in Italian patients with sporadic, diffuse gastric cancer. In this setting, further analyses in large population-based studies are not advisable.

202

POSTER

### Should gastrectomy be performed for metastatic stomach carcinoma?

V. Skoropad, B. Berdov. *Medical Radiological Research Center, Abdominal Dept., Obninsk, Russian Federation*

**Background.** The prognosis of patients with metastatic stomach carcinoma is extremely poor, and there exists controversy on the adequate surgical treatment in terms of safety and benefit.

**Material and methods.** We reviewed the outcome of 56 patients with metastatic gastric cancer in whom total or subtotal gastrectomy ± metastasectomy was performed. The sites of metastases were as the follows: peritoneum (18 patients), distant lymph nodes (16), liver (10), ovary (5), other sites and multiple sites (6). There were 33 males and 23 females; the mean age was 55 years. Tumor-related complications were registered in 40 patient, anemia (17) and pyloric stenosis (15) predominated. The primary tumor penetrated the serosa in 40 patients, involved two thirds or the whole stomach in 32 patients. Lymph nodes were positive in 33 patients. The study population was divided into two equal groups: 28 patients treated between 1975 and 1995, and 28 patients treated between 1996 and 2002.

**Results.** In the second period of the study, the portion of total gastrectomies increased from 39 to 57%, of extended (D2 or more) lymphadenectomy from 7 to 36%. At the same time the incidence of anastomotic leaks decreased from 14 to 7%, intraabdominal infection from 14 to 0%, pneumonia from 18 to 7%; overall number of patients with complications from 36 to 11%. Postoperative mortality was 25% in the former period and 3.5% in the latter. Complete resection of all metastatic sites was performed in 20 (36%) cases, partial resection in 9 (16%) cases. Median survival of the whole group (excluding postoperative deaths) was 8.2 months. Cumulative survival was as the follows: 6 months 76%, 1 year 34%, 2 years 8%. There were only 2 long-term survivors (43 and 115 months), both had distant lymph node metastasis.

**Conclusions.** Gastrectomy, including extended and combined resections, may be performed safely independently of the degree of metastatic extension. It should be performed to patients with metastatic gastric cancer to overcome or to prevent fatal tumor complications. In appropriate cases (P1, H1 etc.), complete metastasectomy may increase the effectiveness of adjuvant therapy and give a patient a chance for cure.

203

POSTER

### Outcome of patients receiving radiation with or without chemotherapy for squamous cell carcinoma of the esophagus

Y. Kagami, A. Imai, Y. Ito, M. Sumi, H. Ikeda. *National Cancer Center Hospital, Radiation Oncology Division, Tokyo, Japan*

**Purpose:** Several studies showed chemoradiotherapy for patients with esophageal cancer was superior radiotherapy alone. There were few studies whether these results were reproduced in practice. Primary objective of this study was to determine outcome of patients with esophageal cancer treated in our institution who received radiation therapy with or without chemotherapy.

**Material & methods:** From 1994 to 2001, 216 patients with squamous cell carcinoma of the esophagus without distant organ metastases were treated with curative intent using radiation therapy alone or combined chemotherapy at National Cancer Center Hospital, Tokyo. There were 186 males and 30 females. The age at diagnosis ranged from 40 to 89 years with a median of 64.5 years old. Forty-eight percent of patients (103 patients) had clinical stage (CS) 1 disease, 17% (37 patients) had CS 2 disease, and 35% (76 patients) had CS 3 disease. Fifty-one patients were treated with radiotherapy alone, and 165 patients were treated with radiotherapy and chemotherapy concurrently. Most of patients treated with chemotherapy were taken cisplatin and fluorouracil.

**Results:** At the time of the analysis, 128 patients were alive and 88 patients were dead. The median duration of follow-up for the patients alive was 27.0 months. A survival rate of all patients at 2 years was 63.6%. Patients, tumor and treatment-related factors were found to be significantly associated with survival on univariate analyses. At 2 years, patients with CS 1 disease had a 88.3% survival rate, compared with 56.3% for the patients with CS 2 and 33.7% for the patients with CS 3 ( $p < 0.0001$ ). Patients who had chemotherapy with radiotherapy concurrently had a 68.5% 2-year survival rate, whereas those who did not had a 2-year survival rate of 44.8% ( $p = 0.0038$ ). Two-year survival rate for patients who presented with a serum albumin level  $\leq 3.7$  g/dl was 70.7%, compared with 58.2% for patients with  $> 3.7$  g/dl ( $p = 0.0459$ ). Survival rate was lower for patients with